IKS014 Hits 50% Response Rate in Post-Enhertu HER2 Breast Cancer: Payload Switch Drives Result

0 points · first seen 19h ago · 1 outlet · 0 comments

Post-Enhertu HER2 breast cancer treatment candidate IKS014 (caxmotabart entudotin) posted a 50% response rate in 10 evaluable patients previously treated with Enhertu -- a setting where Kadcyla returned 0% ORR across 21 patients and the SATEEN combination trial achieved 3.7%. Updated Phase 1 antibody-drug conjugate data will be presented at SABCS on December 9, 2026. — Tech Times

save

· share to X · Bluesky · copy link